Global Viral Vector & Plasmid DNA Manufacturing Market Analysis Report 2019-2025 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 21, 2019--The “Viral Vector & Plasmid DNA Manufacturing Market Analysis Report By Application, By Disease (Cancer, Genetic), By Workflow (Upstream, Downstream), By Vector, By End Use, And Segment Forecasts, 2019 - 2025” report has been added to ResearchAndMarkets.com’s offering.
The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, rising at a 16.0% CAGR during the forecast period.
Rising number of gene therapy-based discovery programs in the pharma industry is one of the key trends driving the production of gene therapy vectors. Moreover, a robust pipeline of viral vaccines and gene therapies has prompted companies to develop novel and effective technologies for scalable manufacturing of vectors. Current vector manufacturing process is considered highly regulated, elaborate, and expensive.
Moreover, at present, there is a shortage of production sites to meet the demand by the pharmaceutical industry for vector construction services. These factors have created opportunities for companies to capitalize on potential avenues in the market through developing novel solutions.
Key growth strategies adopted by companies to sustain their market presence include continuous expansion of manufacturing sites in high-demand markets such as the U.S. and U.K. Moreover, companies are engaged in strategic mergers & facility acquisitions to meet growing requirements of viral vectors within the pharmaceutical and biotech industries and to broaden their service portfolios.
Further Key Findings From the Report Suggest:
Key Topics Covered:
Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement 2.2 Data Analysis 2.3 Market Formulation & Validation 2.4 Approaches for Market Estimation
Chapter 3 Viral Vector & Plasmid DNA Manufacturing Market Variables, Trends & Scope
3.1 Market Segmentation & Scope 3.1.1 Market driver analysis 126.96.36.199 Robust pipeline for gene therapies and viral vector vaccines 188.8.131.52 Technological advancements for vector production 184.108.40.206 Highly competitive market and various marketing strategies undertaken by the operating entities 3.1.2 Market restraint analysis 220.127.116.11 Regulatory, scientific, and ethical challenges associated with gene therapy 3.1.3 Challenge analysis 18.104.22.168 Production capacity challenges 22.214.171.124 Manufacturing challenges pertaining to the production of vector at large scale 3.1.4 Opportunity analysis 126.96.36.199 Facility expansion for cell and gene therapies 188.8.131.52 Investments, collaboration & partnerships in cell and gene therapies space 3.2 Penetration & Growth Prospect Mapping For Vector Type, 2017 3.3 Viral Vector & Plasmid DNA Manufacturing Market-Swot Analysis, By Factor (Political & Legal, Economic And Technological) 3.4 Industry Analysis - Porter’s
Chapter 4 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis
4.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis 4.2 Adenovirus 4.3 Retrovirus 4.4 Plasmid DNA 4.5 AAV 4.6 Lentivirus 4.7 Other Vectors
Chapter 5 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis
5.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis 5.2 Upstream Manufacturing 5.2.2 Vector amplification & expansion 5.2.3 Vector recovery/harvesting 5.3 Downstream Manufacturing 5.3.2 Purification 5.3.3 Fill-finish
Chapter 6 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis
6.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis 6.2 Antisense, RNAi, & Molecular Therapy 6.3 Vaccinology
Chapter 7 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis
7.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis 7.2 Pharmaceutical and Biopharmaceutical Companies| 7.3 Research Institutes
Chapter 8 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis
8.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis 8.2 Cancer 8.3 Genetic disorders 8.4 Infectious diseases 8.5 Others
Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Regional Estimates & Trend Analysis
9.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2017 & 2025 9.2 North America 9.3 Europe 9.4 Asia Pacific 9.5 Latin America 9.6 MEA
Chapter 10 Competitive Landscape
10.1 List of Companies With Portfolio for Vector-based Therapeutic Candidate 10.2 List of Vector Manufacturers 10.3 Strategy Framework 10.4 Market Participation Categorization 10.5 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/dxb9s4/global_viral?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190221005404/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Genomics,Molecular Diagnostics
KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA
INDUSTRY KEYWORD: HEALTH GENETICS
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/21/2019 05:38 AM/DISC: 02/21/2019 05:38 AM